Consortium of lactobacteria strains and method of receiving preparation on its basis, which is used as dietary supplement or ferment for production of sour milk products |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Consortium of lactobacteria strains and method of receiving preparation on its basis, which is used as dietary supplement or ferment for production of sour milk products (RU 2326938):
 Antiphage nutritional broth for activating starter populations / 2326163
The invention may be used for producing dairy products with high quality factors. A nutritional broth comprising skimmed milk, gum arabic, lithium citrate, D-glucosamine, L-rhamnose, D-arabinose, tap water.
Bacteria strain lactococcus lactis subsp diacetilactis ТК-ОБЛ-Д5-5Ф, used for revealing lactococci bacteriophages / 2324733
Invention relates to diary industry, to production of fermented milk products in particular. Bacteria strain Lactococcus lactis subsp. diacetilactis "ТК-ОБЛ-Д5-5Ф" (Russian collection of lactate bacteria for production of cheese and bacteriophages for them at the "ВНИИМС") was obtained from self-sour cream and selected by the sensitivity spectrum for 250 known bacteriophages. It is used as an indicator strain for revealing the lactococci bacteriophages, ways and sources of their spreading at an enterprise. The invention enables one to prevent development of bacteriophages in production of milk produce, to improve its quality and safety for human health, as well as to increase efficiency of the production.
Process of nutrient medium production / 2324732
Lactoserum containing 10% of dry substances will be pasteurised at 90°C during 20 min, cooled to 45°C, reduced with ammonia solution to pH 7.0. Then the Streptococcus thermophilus barm will be introduced and the mixture will be ripened at 40°C during 5 hours, additive will be introduced in the form of milk protein hydrolysate, the mixture will be mixed and sterilised, cooled to 38°C and reduced with ammonia solution to pH 6.8. The nutrient medium thus obtained will enable one to shorten the process of cultivating bifido- and lactobacteria to 24 hours and to increase their concentration when obtaining liquid bacterial concentrate.
 Biocatalist on base of immobilize cells of photosynethic bacteria for producing hydrogen / 2323975
Biocatalyst is made on the base of immobilized cells of photosynthetic bacteria, includes to the matrix of criogel polyvenial alcohol, thanks to which it is produced the hydrogen production. Biocatalist has long time of service, obtain seriously modified productivity and can be used for hydrogen producing in reactors of different types.
Nutrient medium for securing streptococci / 2323969
Nutrient medium contains the pancreatic casein hydrolysate, enzymatic peptone, activator of hemophilic microorganisms' growth, bread yeast, lactose, bromocresol purple, glucose, L-cysteine, sodium sulfite, sodium citrate, sodium azide, crystal violet, agar-agar, distilled water.
Brevibacillus laterosporus bacterium strain inhibiting and preventing development of microphytic algae of various taxonomic types / 2323968
Brevibacillus laterosporus "ВКПМ" В-9405 bacterium strain is separated by means of multistage selection from the natural Brevibacillus laterosporus "ВКПМ" В-8287 strain. The algicide activity is estimated by the strain lytic action on microalgae defining residual optical density (OD). OD is 10.1%. The strain algistatic activity is estimated by defining optical density. The optical density is 1.950.
 Preparation for soil cleaning from arsenic and protection of plants from diseases inhibited by plant pathogenic fungi and preudomonas aureofaciens arc v-2390 d bacterium strain for its making / 2323967
Preudomonas aureofaciens KR31 (pKS1) strain separated from the rhizosphere of alfalfa in Krasnodar Territory and deposited to the All-Russian collection ARC V-2390 D, is capable of inhibiting growth of a wide range of plant pathogenic fungi, stimulates plat growth, resistant to arsenic, dissolves phosphates. Preparation containing Preudomonas aureofaciens bacterium strain cells suspension may be used to clean the soil from arsenic and to protect the plants from the diseases, caused by plant pathogenic fungi.
Bioactive organomineral slow-release fertilizer / 2323918
Organomineral fertilizer, which contains rock phosphate (apatite), natural zeolite, oxidised brown coal in 1:0.15:2-1:0.2:5 ratio, is composted for 30-60 days, while exposed to phosphate-assimilating bacteria in amount of 105-106 cells/spores/ml, isolated from local soil using selection method. Content of labile phosphorus increases from 17.0 to 50.4 mg/kg of soil, and phosphatase activity in chestnut soil increases by 2.8-21.8 times.
Method for preparing halophilic bacterium biomass / 2323251
Method involves culturing halophilic microorganisms in the presence of encapsulated adsorbent and/or antioxidant up to the stationary growth phase in preparing the seeding material. Then in submerged culturing fresh medium is added by portions in the amount 1/3 of the final volume of cultural fluid followed by contacting cultural fluid with an encapsulated adsorbent and/or antioxidant, and additional feeding with dry or concentrated medium is carried out. The amount of dissolved oxygen is maintained at the level 5-10% of the equilibrium level. Invention provides increasing the level of accumulation of biomass, to enhance the specific content of bacteriorhodopsin in halophilic microorganisms biomass and the total yield of bacteriorhodopsin at the minimal content of carotinoids in biomass, and to reduce consumption of nutrient medium also.
Method for preparing halophilic bacterium biomass / 2323226
Method involves using an encapsulated adsorbent and/or antioxidant in preparing seeding material and submerged culturing. In preparing seeding material the culturing process is carried out in freshly prepared nutrient medium up to the stationary growth phase. Submerged culturing is carried out by simultaneous inoculation of bioreactor with seeding material and contacting the content of bioreactor with encapsulated adsorbent and/or antioxidant. The oxygen content in bioreactor is maintained at the level 5-10% of the equilibrium level. Invention provides increasing yield of halophilic microorganisms biomass up to 42 g/l and with the content of bacteriorhodopsin up to 1.6 g/l and in practically absent of carotinoids in biomass. Invention provides reducing time for preparing the unit mass of the end product and to decrease consumptions for production of bacteriorhodopsin.
 Production method for foodstuff (variants) / 2323586
Method consists in: mixing the preparation of viable probiotic microorganisms with additional ingredients, drying till the water activity less than 0.3, mixture pressing under the pressure to receive granules with the volume at least 0.02 cm³, coating with the water-proof protective coat and simultaneously keeping the water less than 0.3 and introduction of granules into liquid, humid and semi-humid food product. The pressing stage may be before drying.
Wound-healing biopreparation as gel / 2322996
Invention relates to producing and using immunobiological preparations comprising Bacillus subtilis biomass. Biopreparation represents a wound-healing gel comprising biomass of antagonistically active strain of Bacillus subtilis 3H or Bacillus subtilis 11B and special additives additionally. Invention provides effective treatment of inflammatory processes on skin and mucosa. Invention can be used in dermatology, gynecology and surgery for topical using.
Immunobiological agent possessing ability for stimulation of human psychoemotional adaptation (variants), and bifidobacterium bifidum 1c strain / 2322252
Invention proposes agents (variants) possessing ability for stimulation of human psychoemotional adaptation. Agent comprises a dry strain of Bifidobacterium bifidum 1C deposited in the State collection of microorganisms representing microorganisms of the normal human microflora - FGUN MNIIEM named for G.N.Gabrichevsky at number 208 and taken in the amount 106 - 1010 CFU (colony-forming units), and pharmaceutically acceptable special additives taken in the amount 30.0-94.0 wt.-% of the agent mass. The proposed immunobiological agent can be represented as dry biomass, powder, tablet being among them as a tablet with an enteric-soluble cover, and capsule being among capsule with an enteric-soluble cover. The strain Bifidobacterium bifidum 1C is prepared by the successive multiple passages through the nutrient medium BS and selection of clones based on the presence and stabilization of a feature for stimulation of the human psychoemotional adaptation. Invention provides enhancing effectiveness of stimulation of human psychoemotional adaptation.
 Method for complex correction of intestinal dysbiosis with the help of liquid probiotic "narine-forte" and prebiotic syrup "phytolon" with chlorophyll / 2322251
The present innovation deals with correcting intestinal dysbiosis due to the intake of probiotic and prebiotic products either within the scope of prophylactic procedures or in complex therapy. The innovation refers to combined peroral intake of liquid concentrated symbiotic lactic acid product of microbial origin "NARINE-FORTE" and Syrup "PHYTOLON" with chlorophyll which should be applied during meals or after meals. The innovation normalizes and protects human intestinal microflora against harmful impact of inadequate nutrition, contaminated environment, stress situations, infections, aftereffects of therapy with antibiotics and other chemopreparations, radiation therapy and other negative actions.
 Lypoteichoic acid from lactic acid bacteria and uses thereof in modulation of immune reactions mediated by gram-negative bacteria and potential pathogenic gram-positive bacteria / 2320356
Invention relates to composition for inhibition or prevention of inflammatory processes associated with bacterium-mediated diseases or LTA/LPS-mediated disturbances in gastrointestinal tract in human or animal. Claimed composition contains as active ingredient lypoteichoic acid from lactic acid bacteria belonging to genus Lactobacillus wherein lypoteichoic acid was selected on the base of its capability of binding to CD 14 and disability of inducing the release of anti-inflammatory cytokines such as IL-8 or TNF-α from enteric epithelial cells. Disclosed is application of at least one lypoteichoic acid from lactic acid bacteria belonging to genus Lactobacillus, and/or lactic acid bacterium producing the same, and/or supernatant of its culture for composition production useful in inhibition or prevention of inflammatory processes associated with bacterium-mediated diseases or LTA/LPS-mediated disturbances in gastrointestinal tract, bones, skin, eyes, ears, lungs, and oral cavity in human or animal.
Method for production of biomass from liquid lactobacterium autostrain / 2320355
Claimed method includes sampling of native material, sample seeding on selective nutrient medium without dilution not later than 2 h after sampling; lactobacterium growing and pure culture isolation. Repeated passage is carried out. Obtained pure lactobacterium culture is grown in selective liquid medium followed by addition of conserving agent such as sucrose-gelatin medium in ratio of 1:1 and controlling of obtained liquid biomass.
 Microorganisms as carriers of nucleotide sequences encoding cellular antigens for treatment of tumors / 2319741
Invention relates to genetically modified microorganism comprising the following components in its genomes that are expressed: (I) nucleotide sequence encoding at least one the tumor cell antigen epitope, and/or nucleotide sequence of at least one antigen epitope showing specificity to tissue cell generating tumor; (II) nucleotide sequence encoding protein that stimulates cell of the immune system; (IIIA) nucleotide sequence of the transport system providing expression of product of components (I) and (II) expression on external surface of microorganism, and/or secretion of product of component (I) and component (II) expression, and/or (IIIB) nucleotide sequence of protein for lysis of microorganism in mammal cells cytosol and for intracellular releasing plasmas containing in microorganisms to be lysed, and (IV) activating sequence activated in microorganism showing specificity to tissue cell but not specific to cell for expression of one or some components from (I) to (IIIB), and wherein each of components from (I) to (IV) can be represented once or many times. Proposed microorganism is useful for using as a drug as component of anti-tumor vaccine. Also, invention describes plasmid or the expression vector for preparing the genetically modified microorganism and a method for its preparing. Vaccine based on genetically modified microorganism represents the improved and overcome immune tolerance with respect to tumors in case for its using for prophylaxis and therapy of tumors.
Method for preventing puerperal complications in cows / 2319493
It is necessary to introduce culture liquid of bacterial strain "Bacillus subtilis TNP-3-DEP" at the dosage of 2 ml thrice at a 10-d-long interval. The innovation normalizes vaginal microbiocenosis and increases immunobiological reactivity.
Strain streptococcus vestibularis slk-92 used in preparing probiotic preparation designated for prophylaxis and treatment of bacterial intestine infection in agricultural young stock animals / 2317328
Strain Streptococcus vestibularis SLK-92 is isolated from calf corpse intestine and deposited in All-Russian State Collection of strains of microorganisms at FGU "All-Union State center for quality and standardization of medicinal agents for animals and fodders", FGU "VGNKI" - 08.12.39. Using the proposed strain in newborn calves and piglets for prophylaxis and treatment of bacterial intestine infections provides reducing their morbidity, to decrease lethality of animals and multiplicity feeding the preparation to agricultural young stock animals. Invention can be used in preparing probiotic preparation possessing prophylactic and curative effect in intestinal infections in agricultural young stock animals caused by pathogenic enterobacteria of genus Escherichia, Proteus, Morganella, Citrobacter, Enterobacter, Klebsiella and Providencia.
 Strain bifidobacterium adolescentis dva-2 used for preparing fermented and nonfermented foodstuffs, hygienic and cosmetic agents, biologically active supplements and bacterial preparations / 2317327
Invention proposes the strain Bifidobacterium adolescentis DVA-2 that that is isolated from the health adult human intestine content and can be multiplied in different nutrient media with accumulation of industrial biomass with the high concentration of bifidobacteria. The strain Bifidobacterium adolescentis DVA-2 possesses acid-forming activity, antagonistic activity with respect to pathogenic and opportunistic microorganisms. Invention provides normalization of microbiocenosis of human body and among them digestive and urogenital tracts, cutaneous and mucosa tissues, and expands assortment of similar agents also.
 Probiotic strains of lactobacillus (variants) and their using / 2316586
Invention relates to novel probiotic strains of lactobacilli: Lactobacillus acidophilus DSM 14869, Lactobacillus paracasei DSM 14870, Lactobacillus acidophilus DSM 15525, Lactobacillus plantarum DSM 15524, Lactobacillus sp. DSM 11526 and the strain Lactobacillus sp. DSM 15527. Strains shows similar favorable properties used separately or in combination as probiotics or in common with prebiotic as symbiotic. Also, invention relates to pharmaceutical compositions, dairy foodstuffs, functional foodstuffs, nutrient supplements and agents for personal hygiene comprising strains in separately or in combination, and to using strain for prophylaxis or treatment of vaginal infections, urogenital infections and gastrointestinal diseases.
|
FIELD: technological processes; medicine. SUBSTANCE: consortium of lactobacteria strains contains Lactobacillus acidophilus 57S ("ВКПМ В-5863"), Lactobacillus piantarum "П-75" ("ВКПМ В-3962"), Lactobacillus casei stilb ("ВКПМ В-5724"), which are taken in proportion of 2:0.5:0.5. The method includes preparation of milk nutrient medium, its sterilisation and cooling down to the temperature of fermentation, introduction of inoculation dose of lactobacteria strains consortium in the quantity of not more than 5.0 mass %. The product is fermented during time, which is sufficient for formation of clot and the ready product is cooled at the temperature of not more than +6°C. As milk nutrient medium non-fat milk is used, normalised in solid residual down to 13.5-15%, lactopeptone and lithium citrate with the following proportion of components, (mass %): lactopeptone - 3.5-4.5, lithium citrate - 0.15-0.25 and non-fat milk, normalised in solid residual down to 13.5-15% - the rest. EFFECT: increases shelf life and initial titre of lactobacteria consortium in prepared substance. 4 cl, 4 tbl, 5 ex
The technical field The invention relates to biotechnology and medical Microbiology and is a consortium of strains of lactobacilli, which can be applied to obtain a drug used as biologically active additives (BAA) or yeast for the production of fermented milk products for medicinal and dietary purposes. The function of the normal microflora in the body are vital and very extensive: synthesizing, regulatory, desensibiliziruyuschee, detoxification, enzyme, protective and immunostimulirutuyu. Preparations and products containing lactobacilli are widely used for the prevention and treatment of dysbacteriosis and normalization of the intestinal microflora of people undergoing stress, antibiotic and chemotherapy. Prior art Abroad widely used drugs probiotics and health food products based consortia strains of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus delbrueckii, Lactobacillus fermentum and Lactobacillus lactis in different combinations (U.S. Patent No. 6827953, IPC 12N 1/20, AK 35/72, publ. 07.12.2004; UK patent No. 883424, IPC SS 1/20, publ. 29.11.1961; UK patent No. 930107, IPC AC 35/72, publ. 03.07.1963), and also on the basis of consortia strains of bifido - and lactobacteria the th (Application U.S. No. 20020090416, IPC A23L 1/00, publ. 11.07.2002; U.S. patent No. 5866385, IPC 12N 1/21, AS 9/123, publ. 02.02.1999). However, consortia strains of lactobacilli and consortia strains of bifidobacteria and lactobacilli foreign firms-developers focused on creating mainly therapeutic and preventive drugs and SUPPLEMENTS in dry form (tablets, capsules). These consortia strains have significant shortcomings when used for cooking preparations and dairy products in liquid form: short term storage of these drugs and products, low organoleptic qualities that are irrelevant to drugs in the dry form. Known consortia strains of bifido - and lactic acid bacteria used for the production of fermented and non-fermented products in liquid form (RF Patent No. 2180348, IPC 12N 1/20, publ. 2002; RF patent №2180914, IPC 12N 1/20, publ. 2002; RF patent №2180915, IPC 12N 1/20, publ. 2002). The main disadvantage of dairy products manufactured on the basis of consortia strains of bifidobacteria and lactobacilli is the lack of retention period (not longer than 1 month) due to the fact that lactic acid bacteria during storage of the product contribute to rapid acidification. The titer of bifidobacteria in zakislenna product decreases rapidly, which reduces treatment-and-prophylactic properties of this product. Most BL is skim technical solution (prototype) is a consortium of strains of lactobacilli Lactobacillus acidophilus (strain NCIMB 40354), Lactobacillus plantarum (strain NCIMB 40356); Lactobacillus casei (strain NCIMB 40357)used to obtain dairy therapeutic products (UK patent No. 2251864, IPC 12N 1/20, publ. 22.07.1992). However, the shelf life of such a consortium of strains of lactic acid bacteria in fermented milk products is 30 days, which is insufficient in the preparation of biologically active additives in liquid form. Other the closest technical solution (prototype) is a method for the preparation of 15 symbiotic cultures of bacteria-probiotics as bifidobacteria and lactobacilli, including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei (RF patent No. 2163445, IPC AS 9/12, publ. 27.02.2001,), which can be used as a therapeutic drug or a dietary Supplement in liquid form. The method involves the multiplication of each monoculture bacteria-probiotics on the environment separately at optimum temperatures in the range of 20-25°C for 12-16 hours prior to the formation of a clot in thermos. Next, produce a drain of each monoculture in a sterile container in a ratio by volume of 1:1 and the mixture is stirred. Later in sterile skim milk or milk with a fat content of 0.5 to 3.2% contribute 3-5% of a mixture of monocultures, mixed and placed in a thermostat for 5-7 hours at a temperature of 32-37°to the formation of a clot and up to 108-9 cells in 1 g of Finished drug put in the refrigerator at 0-6°C. However, the preparation obtained in this way has a low initial titer of the finished product (up to 108-9cells in 1 g) and short shelf life. Lactobacilli during storage of the product contribute to its acidification, resulting titer of lacto - and bifidobacteria in zakislenna product decreases rapidly, resulting in a decrease in therapeutic and prophylactic properties. The technical result of the claimed technical solution is to increase the retention of the proposed consortium of lactic acid bacteria in cooked products, including dietary Supplements, as well as ensuring higher initial titer of the finished products after their preparation. This technical result is achieved by a new consortium of strains of lactobacilli Lactobacillus acidophilus 57S (deposited in the Institute of genetics in PMBC under No 5863), Lactobacillus plantarum P-75 (deposited in the Institute of genetics in PMBC under No 3962); Lactobacillus casei SS (deposited in the Institute of genetics in PMBC under No 5724), used to obtain the liquid form of dietary supplements and dairy therapeutic products. The number of Lactobacillus acidophilus 57S, Lactobacillus plantarum P-75; Lactobacillus casei Sat correlate 2:0,5:0,5. This technical result is also achieved by the fact that in the method of obtaining biologically active add and bacteria-probiotics in liquid form, including the preparation of dairy nutrient medium, sterilized and cooled to the fermentation temperature, the introduction of dairy nutrient medium sowing dose combinations of strains of bacteria-probiotics in the amount of not more than 5.0 wt.%, the fermentation product in a period of time sufficient for formation of a clot, and cooling the finished product at a temperature not higher than +6°Since, according to the invention, as a combination of strains of bacteria-probiotics use a consortium of strains of lactobacilli Lactobacillus acidophilus 57S (deposited in the Institute of genetics in PMBC under No 5863), Lactobacillus plantarum P-75 (deposited in the Institute of genetics in PMBC under No 3962); Lactobacillus casei SS (deposited in the Institute of genetics in PMBC under No 5724)contained in a ratio of 2:0,5:0,5, and as a dairy nutrient use skim milk milk, normalized to the dry residue SOMO of 13.5-15%, which further added lactate and sodium citrate in the following ratio of components (wt.%):
Moreover, the fermentation is carried out at a temperature (39-40) C for 4-5 hours before reaching the acidity of the finished product is not less than 90°So In the standard fat-free dairy environment artificially increase 1.3-1.5 times the concentration of proteins and lactose making powdered milk to nonfat dry milk solids (SNF) was reached 13.5-15%. The higher the SNF content, the higher content of casein, which forms a buffer system, linking a large number of acidic metabolites in the Caseinates. Thereby it is possible to restrain the increase of the pH during the growth of biomass. In addition, with an increase of up to 15% SNF in milk products milk increases the amount of lactose by 25-30%, which increases the growth properties of the environment, providing a higher titer of lactobacilli. To prevent coagulation of the casein in the milk base, introduce a solution of sodium citrate, which has a strong stabilizing and buffer properties. Bactopeptone introduced to increase the growth properties of dairy nutrient medium, which is a hydrolysate of whey proteins (α-lactalbumin, β-lactoglobulin, immunoglobulin, lactoferrin), which after cleavage give a large number of irreplaceable and sulfur-containing amino acids. The result was to significantly increase the safety of lactic acid bacteria consortium. Optimization of technology received the I biomass of lactobacilli on fat-free dairy environment with a high content of SNF and bactopeptone, allowed to obtain a stable biomass with high initial titer and long shelf life. Information on the Deposit of strains consortium: 1. Lactobacillus acidophilus 57S (deposited in the Institute of genetics in PMBC under No 5863); 2. Lactobacillus plantarum P-75 (deposited in the Institute of genetics in PMBC under No 3962). 3. Lactobacillus casei SS (deposited in the Institute of genetics in PMBC no In - 5724). Properties of the consortium determines the strain of lactic acid bacteria Lactobacillus acidophilus 57S, the content of which in the consortium of about 70%. Cultural morphological traits consortium Cells of lactobacilli are straight sticks of medium length or large (1.0 to 1.5×3-14 μm)that are chains or singly, gram-positive, spore and capsule form. In dense environments form a shallow depth colonies, usually in the form of a tangle of threads. Strains not liquefy gelatin, do not form gas, catalase does not produce. Synthesize lactic acid, assimilate glucose, arabinose, lactose, not assimilate raffinose, sucrose, maltose, mannitol. The optimum temperature for growth of strains of lactobacilli is (36-42)°C. When introducing strains in the skim milk in the amount of 3%, the fermentation of milk takes 4-5 hours. The acidity of the consortium is 240-280°So Acid-forming activity by 24 h - 140° Turner, 72 h 160-200�B0; Turner. The maximum titer of lactobacilli consortium in the dairy environment (sterile skim milk) after 5-6 hours growth is 1-2×109after 90 days of storage in this environment - 1-2×108. When adding bactopeptone after 4-5 h of growth is (3-7)·1010after 90 days of storage in this environment - 2,5-6×109 Antagonistic properties: Shows activity against Shigella sonnei, Flexner, enteropathogenic enteric rods, staphylococci. The ability of the consortium strains of three species of lactic acid bacteria to increase microbial mass in nutrient media, skachivat milk in a short time, to show specific activity makes possible its use in the preparation of dietary supplements, dairy, not fermented foods and bacterial preparations. The results of the studies supporting the beneficial properties of the proposed consortium of strains of lactobacilli To identify technological features and properties of the proposed consortium of strains of lactobacilli studies in the cultivation process of the proposed consortium, as well as its storage. Cultivation consortia conducted in the dairy environment, made by MUK 4.2.577-96 Methods of microbiological control of products for children, therapeutic feeding and their component is in". To improve the growth properties of dairy framework was introduced bactopeptone (wt.%):
In the standard fat-free dairy environment artificially increase 1.3-1.5 times the concentration of proteins and lactose making powdered milk to nonfat dry milk solids (SNF) was reached 13.5-15%. The higher the SNF content, the higher content of casein, which forms a buffer system, linking a large number of acidic metabolites in the Caseinates. Thereby it is possible to restrain the increase of the pH during the growth of biomass. The higher lactose content, the higher the growth properties of the environment - increasing the lactose content of 25-30% increases the titer of lactobacilli. To prevent coagulation of the casein in the milk base, introduce a solution of sodium citrate, which has a strong stabilizing and buffer properties. In addition, to enhance the growth properties of dairy nutrient medium injected bactopeptone, which is a hydrolysate of whey proteins (α-lactalbumin, β-lactogal is in, immunoglobulin, lactoferrin), which after cleavage give a large number of irreplaceable and sulfur-containing amino acids. The result was to significantly increase the safety of lactic acid bacteria consortium. Optimization of technology for biomass lactobacilli on fat-free dairy environment with a high content of SNF and bactopeptone allowed to obtain a stable biomass with high initial titer and long shelf life. Table 1 presents the technological characteristics of the proposed consortium of strains of lactic acid bacteria in the dairy environment (mainly milk, normalized to the dry residue of 13.5-15%) during cultivation and storage.
Study the antagonistic activity of the proposed consortium of strains of lactobacilli Antagonistic activity of strains consortium of lactobacilli (table 2) was studied by the method of in vitro when the joint cultivation of pathogenic test strains in the zone of growth inhibition of the test microbes method barcodes
Study of the influence of the consortium of lactobacilli on the representatives of the normal intestinal microflora in model in vitro. These studies were conducted Leading test centre at the Institute of Nutrition Russian Academy of medical Sciences. The objects of research - drugs-eubiotics of production of JSC "BIOMED" them. Sechenov: - Lactobacterin dry, - Bifidumbacterin dry
From table 3 it can be seen that the inhibitory effect of a consortium of lactobacilli on the representatives of the normal intestinal microflora in model in vitro was not observed. The effectiveness of the consortium of strains of lactobacilli was established in the preclinical studies conducted in the SRC VB "Vector" of the RF Ministry of health on adult mice and calves genetically standard colony ICR in accordance with the requirements of RD 42-28-8-89 "Preclinical trials of new biologic drugs. Basic provisions". The study was conducted according to the scheme: General toxicity (chronic), embryotoxicity and the impact on the reproductive function, the overall pharmacological effect (the effect on the digestive system, the formation of the adaptation effect). In the study of chronic toxicity all animals were viable, loss of body weight, disorders of motor activity, state oppression and death is not marked. Moreover, there is a stimulating effect consortium on ro is t, the development and survival of animals. Hematological parameters of blood within the physiological norm. Histological examination of the organs showed no toxic effects on these organs. Not identified as immunotoxic effects on the organs of the lymphoid system in their histological examination. High efficiency consortium of lactobacilli proved in the study of reproductive function in pregnant females - there is a noticeable improvement in body condition of females, reducing late embryonic mortality after implantation (3,1%) against (5,3%) in the control group, the better the survival rate of newborns during this period reached 92.5% in comparison with control up to 80%. To test the effectiveness of the physiological impact of the consortium on the digestive system of mice showed a stabilizing effect on the digestive tract and the formation of microflora of newborn mice due to colonization activity of strains of lactic acid bacteria consortium. The consortium also promotes survival of mice in difficult situations (conditions of elevated temperatures - 32+2° (C)acting as an adaptogen, promoting the preservation of significant functional reserves of vitally important systems of the body. Examples of the preferred embodiment of the invention Example 1. Obtaining, based on the e of the proposed consortium of lactobacilli SUPPLEMENTS "TRIACT or yeast for the production of fermented milk products Introduction cultures of lactobacilli. For preparation of primary fallopian leaven use freeze-dried certified strains of lactobacilli Lactobacillus acidophilus 57S, Lactobacillus casei Sat and Lactobacillus plantarum P-75 or the same activated Museum strains were stored in test tubes in a sterile non-fatty milk. In a vial with liofilizirovannam certified strain of lactobacilli pipette contribute (0.2 to 0.5) ml of sterile saline. After dissolution of freeze weight the same pipette the contents of the ampoule subcultured (transferred) in a test tube with 9 ml of sterile skim milk and mix well by pipetting. Crops are incubated in thermostat TS at a temperature (39,0-40,0)°for (20-24) hours. Then hold 1-2 passage in glass vials (0,1-0,25) l with sterile skim milk for full activation of their properties. Subsequent crops incubated in a thermostat at a temperature of 39.0-40,0)°for (5-6) hours. After incubation vials cultures is passed for cooling and storing in the fridge after ripening for 10-12 hours are used to obtain laboratory yeast. Primary fallopian sourdough lactobacilli may be stored in a refrigerator at a temperature of (6-8)°With no more than 7 days. Preparation of laboratory and industrial sourdough strains lactoba is clear. Laboratory sourdough lactobacilli produce sterile non-fatty milk from primary fallopian ferment separately for each strain of lactobacilli based weekly needs and use in further production on the next day after cooking. Alternately vial cultures of lactic acid bacteria with a characteristic growth in sterile fat-free milk, pipetted culture of each of the strains in the amount of 3% inoculum volume of sterile skim milk. Incubated for (4-5) hours at a temperature of (39±1)°C. The content of probiotic microorganisms in the biomass of lactobacilli is lg 8-9 in 1 ml. Obtaining a consortium of lactobacilli. To obtain consortium of strains of lactobacilli produce mechanical mixing of lab starter cultures Lactobacillus acidophilus 57S, Lactobacillus plantarum P-75, Lactobacillus casei Sat in the ratio 2:0,5:0,5. The content of probiotic microorganisms in the biomass consortium Association is lg 9 in 1 ml. Getting the starter or BAD "Trilock. The preparation of the starter culture or biomass BAD "Triact" are exceptions in sterile glass bottles with a capacity of 15 liters In the beginning prepared in aseptic conditions dairy nutrient medium on the basis of skim milk milk, normalize is spent on the dry rest SOMO to 13.5 to 15.0%. In specified dairy environment further added lactate and sodium citrate in the following proportions (wt.%):
Under aseptic conditions in a glass bottle containing 9.5 litres normalized dairy nutrient medium, make a finished production leaven consortium of lactobacilli in the amount of 0.5 L. Microbial mixture of lactobacilli gently stirred in a circular rotation of the bottle during (1-2) minutes. Placed in a thermostat type TC-80M (4-5) hours at the temperature (39-40)°C. the Fermented mixture is left without stirring until the formation of a clot and achieve the acidity of not less than 90°So After the formation of a clot bottles product zakolerovat to temperature (4±2)°in refrigerators. To stabilize and strengthen the clot cooling down, the product is made in (8-10) h with subsequent packaging and storage of finished product. Example 2. The use of the consortium as a starter for the preparation of symbiotic fermented milk product treatment and functional PI is project - Upazila The leaven of the consortium, prepared according to example 1, in the order of 0.5-1% make pasteurized milk with bacteria and thermophilic Streptococcus in the amount of sourdough provided for making upazila, mix and cultivate 3-3,5 h until the formation of a clot, then the product is cooled and Packed in consumer packaging. As a result of receiving treatment-and-prophylactic milk product content useful follow-not less than lg 7-8 in 1 ml of symbiotic product. The resulting product has a pronounced immunocorrective action. Example 3. The use of a consortium of strains of lactobacilli for obtaining bacterial drug To grown biomass consortium of example 1 add a protective environment drying (sucrose 10% gelatin 5%). The resulting suspension is poured into 2 ml ampoules or 5 ml vials, frozen at t = minus 40-45°and lyophilizers from the frozen state in a vacuum drying apparatus. The resulting preparation contains not less than 109living cells of lactic acid bacteria. Production technology consortium in the composition of the products does not require expensive equipment (fermenters) and produces large amounts of biomass lactobacilli simple thermostatic means without the correct pH and application systems gatooma the and. At the same time, the concentration of lactobacilli in biomass consortium of lactobacilli reaches maximum values - lg 10. Acidity biomass lactogen-sortium even when stored for 3 months in a liquid state increases, within limits. In the proposed consortium of more technological and economical in comparison with other forms of consortia, very easy to use, storage and transport. Example 4. Study of the retention of the consortium of strains of lactic acid bacteria in liquid SUPPLEMENTS "Triact" Investigated the duration of storage of the consortium of strains of lactic acid bacteria in liquid SUPPLEMENTS "Triact (table 4). A considerable time (up to 108 days) storage BAD "Triact" titre not less than 108CFU/ml is associated with providing the initial acidity of the drug consortium of lactobacilli (120-140)°T, obtaining the original title of lactobacilli (not below 109CFU/ml) and original dairy nutrient medium with the addition of bactopeptone.
Example 5. The use of dietary SUPPLEMENTS "Triact" for the correction of disorders of intestinal biocenosis with somatic diseases involving dysfunction of the digestive system. Clinical trials have been conducted on the basis of the Novosibirsk Oblast children's allergodermatozov centre on the basis of the MUSES DGKB No. 1, clinical diagnostic and bacteriological laboratories of the specified hospital; Novosibirsk center of family rehabilitation. The most important role in the life of the human body plays a normal microflora of the intestine that inhibits the growth of pathogenic, spoilage and gas-forming organisms, participating in the metabolism and synthesis of vitamins, stimulating the immune system. Violation of the qualitative and quantitative composition normoflora called dysbiosis leads to diseases of the digestive system, the blood, the immune system, the development of malnutrition, anemia, fermentopathy contributes allergization of an organism. Therefore, the prevention and treatment of disorders of intestinal biocenosis is the object of special attention. BAD "Triact" is a microbial mass of live lactobacilli produced according to example 1 and restores the normal microflora composition Ki is ecnica. The study included 30 patients: children aged 6 months and adults aged 50 years, with the dysbacteriosis is not above 3 degrees, not suffering from viral hepatitis and gave informed consent for research. The comparison group consisted of 30. Clinical symptoms of the disease before treatment were malaise, weakness, headache, sleep disturbance (73,3%); diarrhoea syndrome in the form of loss of appetite, flatulence, nausea (53,3%); abdominal pain (50,0%); diarrhea as chronic constipation (53,3%) and diarrhoea (13.3%), alternating constipation and diarrhea (3.3 percent). At 53.3% of subjects noted skin syndrome in the form of rash and lesions of atopic dermatitis in the subacute stage of an exacerbation. All 30 people included in the experiment (100,0%)were dysbiotic disorders of the intestine: a dysbacteriosis of I degree in 24 (80,0%), goiter II degree in 6 (20,0%). 19 out of 30 people (63,3%) had an increased titer of conditionally pathogenic bacteria in the intestinal microflora, 20 (66,7%) were atypical and enzymatic defective strains of E. coli. Treatment using SUPPLEMENTS "Triact" accounted for 14 days in a dose of age, provided instructions for use: - children from 6 months to 1 year on the advice of a physician up to 5 ml (1 teaspoon) per day in 2 doses, - children from 1 year to 7 years - 5 mln 1 reception 2 times a day, - children from 7 to 12 years : 5 ml per 1 reception 3 times a day adults and children over 12 years : apply 10 ml (1 tbsp) 1 reception 3 times a day. The control group were treated by standard therapy. The study used the drug close to the expiration date. According to the results of the assessment of clinical effectiveness study drug was found that the improvement of health in the form of a normalization of sleep, stop headaches and discomfort was noted in 18 out of 22 (81.8 percent), had these symptoms in 4 people have decreased significantly. Reduction of dyspeptic symptoms (disappearance of nausea, decrease flatulence and improving appetite) were observed in 9 of 16 (56.3 per cent); cessation of abdominal pain in all 15 people (100,0%) with given symptoms. Normalization frequency and stool consistency was observed in 17 of 21 (80,9%) of the subject, a clear positive trend cutaneous syndrome was observed in 10 out of 16 (62.5%) and children with atopic dermatitis and recurrent urticaria improved the intestinal function, 22 patients disappeared discomfort, flatulence and borborygmus. 5 patients were noted cessation of diarrhea on the first day, in 18 patients cropped locks. All observed patients has improved the composition of the microflora of the colon. By the end of treatment in 24 patients was significantly increased quantity and the creation of anaerobic microorganisms bifidobacteria and lactobacilli, reduced the number of conditionally pathogenic microorganisms. Thus, the study drug is clinically tested and can be considered harmless and is highly active against recovery normalizes bowel and acceleration sanogenesis with somatic diseases involving dysfunction of the digestive system. These examples show that the proposed consortium strains of three species of lactobacilli actively propagated in nutrient media with the accumulation of biomass production in a short period of cultivation. Product skachivat milk with the formation of the clot with good taste and organoleptic properties; has a specific activity. The consortium strains can be recommended as part of starter cultures for making SUPPLEMENTS "Triact", milk treatment and diet products, non-fermented food and bacterial preparations. Industrial applicability The above description of the invention sets forth the entire Tekhnologicheskiy the process of obtaining the consortium and products on its basis, which can be set either at milk kitchens and large dairies. Used culture media and reagents available to the public. Tools and techniques for getting and growing biomass consortium, is in the form of laboratory and production of starter cultures and the tools and techniques that provide freezing and lyophilization of dried bacterial preparation, traditionally used in the medical industry and biotechnology. 1. The consortium of strains of lactobacilli Lactobacillus acidophilus 57S (deposited in Vniigenetika in PMBC under No 5863), Lactobacillus plantarum P-75 (deposited in Vniigenetika in PMBC under No 3962); Lactobacillus casei SS (deposited in Vniigenetika in PMBC under No 5724), used to obtain the liquid form of dietary supplements and dairy therapeutic products. 2. The consortium of strains of lactic acid bacteria according to claim 1, characterized in that the number of Lactobacillus acidophilus 57S, Lactobacillus plantarum P-75; Lactobacillus casei Sat correlate 2:0,5:0,5. 3. The method of obtaining the drug, used as a dietary Supplement or yeast for the production of dairy products, including the preparation of dairy nutrient medium, sterilized and cooled to the fermentation temperature, the introduction of dairy nutrient medium sowing dose combinations of strains of bacteria-probiotics in the amount of not more than 5.0 wt.%, the fermentation product in a period of time sufficient for formation of a clot, and cooling the finished product at a temperature not higher than 6°C, characterized in that the combination of strains of bacteria-probiotics use a consortium of States the MOU lactobacilli Lactobacillus acidophilus 57S (deposited in Vniigenetika in PMBC under No 5863), Lactobacillus plantarum P-75 (deposited in Vniigenetika in PMBC under No 3962), Lactobacillus casei SS (deposited in Vniigenetika in PMBC under No 5724)contained in a ratio of 2:0,5:0,5, and as a dairy nutrient use skim milk, normalized to the dry residue to 13.5-15%, which further added lactate and sodium citric acid in the following ratio, wt.%:
4. The method according to claim 3, characterized in that the fermentation is carried out at a temperature of 39-40°C for 4-5 h until the pH of the finished product is not less than 90°So
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||